S F Sobhan, M Shafiquzzaman, M R Islam, S Fardous, M O Farook
{"title":"Solitary Morphea Profunda: A Case Report.","authors":"S F Sobhan, M Shafiquzzaman, M R Islam, S Fardous, M O Farook","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Morphea is an autoimmune connective tissue disease that leads to sclerosis of skin and underlying subcutaneous tissue due to excessive collagen deposition. It is also called localized scleroderma. Morphea profunda is one of the morphological variants of morphea. It involves the deep dermis, subcutaneous tissue, fascia and muscle. Morphea profunda is characterized by one or more deep sclerotic plaque, thickened skin with hypo or hyper-pigmentation occurring mostly in abdomen and extremities. Lesions usually progress slowly and remain stable for years. Diagnosis of morphea is made by characteristic clinical appearance but for determination of depth and degree of involvement, histopathology is required in most cases. There is a morphea specific skin scoring system LoSCAT by which grading of the disease is done clinically. Treatment of morphea includes topical and systemic medication like Tacrolimus (0.1%), Imiquimod, Calcipotriol, methotrexate and PUVA. Our patient a 12 year old girl presented with a depressed hypopigmented lesion on left arm which she noticed incidentally. The lesion appeared on the lateral aspect of left upper arm and gradually extending deep and also increasing in size for last few months with sparse hair and loss of sensation over the lesion. Disease activity and severity was assessed by LoSCAT, a morphea scoring system. By LoSCAT it was found that the disease was moderately active but there is greater damage caused by the disease. On routine investigation all parameters are normal and was ANA was (-ve). The diagnosis was confirmed by skin biopsy for histopathology. The patient was treated with methotrexate.</p>","PeriodicalId":94148,"journal":{"name":"Mymensingh medical journal : MMJ","volume":"34 2","pages":"571-575"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mymensingh medical journal : MMJ","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Morphea is an autoimmune connective tissue disease that leads to sclerosis of skin and underlying subcutaneous tissue due to excessive collagen deposition. It is also called localized scleroderma. Morphea profunda is one of the morphological variants of morphea. It involves the deep dermis, subcutaneous tissue, fascia and muscle. Morphea profunda is characterized by one or more deep sclerotic plaque, thickened skin with hypo or hyper-pigmentation occurring mostly in abdomen and extremities. Lesions usually progress slowly and remain stable for years. Diagnosis of morphea is made by characteristic clinical appearance but for determination of depth and degree of involvement, histopathology is required in most cases. There is a morphea specific skin scoring system LoSCAT by which grading of the disease is done clinically. Treatment of morphea includes topical and systemic medication like Tacrolimus (0.1%), Imiquimod, Calcipotriol, methotrexate and PUVA. Our patient a 12 year old girl presented with a depressed hypopigmented lesion on left arm which she noticed incidentally. The lesion appeared on the lateral aspect of left upper arm and gradually extending deep and also increasing in size for last few months with sparse hair and loss of sensation over the lesion. Disease activity and severity was assessed by LoSCAT, a morphea scoring system. By LoSCAT it was found that the disease was moderately active but there is greater damage caused by the disease. On routine investigation all parameters are normal and was ANA was (-ve). The diagnosis was confirmed by skin biopsy for histopathology. The patient was treated with methotrexate.